Abstract

Prolactinomas represent the most common type of secretory pituitary neoplasms, with a therapeutic management that varies considerably based on tumour size and degree of hyperprolactinemia. The aim of the current study was to evaluate the relationship between serum prolactin (PRL) concentrations and prolactinoma size, and to determine a cut-off PRL value that could differentiate micro- from macro-prolactinomas. A retrospective cohort study of 114 patients diagnosed with prolactinomas between 2007 and 2017 was conducted. All patients underwent gadolinium enhanced pituitary MRI and receiver operating characteristic (ROC) analyses were performed. 51.8% of patients in this study were men, with a mean age at the time of diagnosis of 42.32 ± 15.04 years. 48.2% of the total cohort were found to have microadenomas. Baseline serum PRL concentrations were strongly correlated to tumour dimension (r = 0.750, p = 0.001). When performing the ROC curve analysis, the area under the curve was 0.976, indicating an excellent accuracy of the diagnostic method. For a value of 204 μg/L (4338 mU/L), sensitivity and specificity were calculated at 0.932 and 0.891, respectively. When a cut off value of 204 μg/L (4338 mU/L) was used, specificity was 93.2%, and sensitivity 89.1%, acceptable to reliably differentiate between micro- and macro- adenomas.

Details

Title
Identification of an optimal prolactin threshold to determine prolactinoma size using receiver operating characteristic analysis
Author
Leca, Bianca M 1 ; Mytilinaiou, Maria 1 ; Tsoli Marina 2 ; Epure Andreea 3 ; Aylwin Simon J B 4 ; Kaltsas Gregory 2 ; Randeva, Harpal S 5 ; Dimitriadis, Georgios K 6   VIAFID ORCID Logo 

 University Hospitals Coventry and Warwickshire NHS Trust, Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), Coventry, UK (GRID:grid.15628.38) 
 University of Athens, 1st Department of Propaedeutic Internal Medicine, Endocrine Unit, National and Kapodistrian, Athens, Greece (GRID:grid.5216.0) (ISNI:0000 0001 2155 0800) 
 Achilles Information Limited, Abingdon, UK (GRID:grid.5216.0) 
 King’s College Hospital NHS Foundation Trust, Department of Endocrinology ASO/EASO COM, London, UK (GRID:grid.429705.d) (ISNI:0000 0004 0489 4320) 
 University Hospitals Coventry and Warwickshire NHS Trust, Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), Coventry, UK (GRID:grid.15628.38); University of Warwick, Division of Reproductive Health, Warwick Medical School, Coventry, UK (GRID:grid.7372.1) (ISNI:0000 0000 8809 1613); Aston University, Aston Medical Research Institute, Aston Medical School, Birmingham, UK (GRID:grid.7273.1) (ISNI:0000 0004 0376 4727) 
 King’s College Hospital NHS Foundation Trust, Department of Endocrinology ASO/EASO COM, London, UK (GRID:grid.429705.d) (ISNI:0000 0004 0489 4320); University of Warwick, Division of Reproductive Health, Warwick Medical School, Coventry, UK (GRID:grid.7372.1) (ISNI:0000 0000 8809 1613); King’s College London, Department of Obesity, Immunometabolism and Diabetes, School of Life Course Sciences, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2522965167
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.